Repligen Co. (NASDAQ:RGEN) Director Buys $37,672.50 in Stock

Repligen Co. (NASDAQ:RGEN) Director Margaret Pax acquired 250 shares of the company’s stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Repligen Trading Up 0.4 %

Shares of RGEN opened at $144.88 on Thursday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $200.23. The company has a 50-day moving average of $156.78 and a 200 day moving average of $148.46. The firm has a market capitalization of $8.12 billion, a price-to-earnings ratio of -284.08, a PEG ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. On average, research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Institutional Investors Weigh In On Repligen

Several large investors have recently modified their holdings of RGEN. Signaturefd LLC raised its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in shares of Repligen in the 4th quarter valued at about $29,000. Raiffeisen Bank International AG bought a new stake in shares of Repligen in the 4th quarter valued at about $29,000. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the 3rd quarter valued at about $37,000. Finally, Quarry LP raised its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on RGEN. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a report on Tuesday. They issued an “in-line” rating and a $155.00 target price for the company. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.